Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company’s ...

A high-level overview of Stoke Therapeutics, Inc. (STOK) stock. View (STOK) real-time stock price, chart, news, analysis, analyst reviews and more.

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $17.58. The stock has a market capitalization of $608.21 million, a price-to-earnings ratio of -5.30 and a beta of 1.09.

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

BEDFORD, Mass., June 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

BEDFORD, Mass., June 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has ...

In May, Biogen and City Therapeutics, Inc., a privately held biopharmaceutical company, announced a strategic collaboration to develop select novel RNAi therapies.